Zydus Cadila's Virafin aids in India's fight against COVID; President Samir Desai lists benefit | Exclusive

Amid the ongoing COVID crisis in the country, the vaccine supply shortage is becoming a cause of concern. Zydus Cadila's drug to treat moderate COVID cases was recently approved by the DCGI. Times Now speaks to Samir Desai, President, BU, Zydus Group.

The approval that Virafin received from the DCGI was after a successful phase three trial which was conducted in India. The use of Virafin will be at a stage when the virus initially infects our body and will usually be the first line of defence, adds Samir Desai. A month after Zydus Cadila received an emergency use authorization for Virafin, the firm discusses the life-saving drug and its benefits.


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting